Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 7/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927534 | 0.91 | HTR4 (0.42) | PTK2SUV39H2HTR4HSP90AB1BRD4 | |
| SCHEMBL4095634 | 0.91 | PTK2 (0.42) | PTK2BRD4PLK1BRDT | |
| SCHEMBL4094726 | 0.85 | LRRK2 (0.41) | SUV39H2HSP90AB1LRRK2 | |
| SCHEMBL13928051 | 0.82 | BRD4 (0.43) | PTK2BRD4PLK1BRDTLRRK2 | |
| SCHEMBL4096792 | 0.81 | HSP90AB1 (0.42) | SUV39H2HSP90AB1LRRK2 | |
| SCHEMBL4092353 | 0.80 | SRC (0.38) | HSP90AB1LRRK2 | |
| SCHEMBL4102760 | 0.78 | HSP90AB1 (0.41) | HSP90AB1 | |
| SCHEMBL15101684 | 0.77 | LRRK2 (0.47) | SUV39H2LRRK2 | |
| SCHEMBL14642199 | 0.76 | LRRK2 (0.43) | SUV39H2LRRK2 | |
| SCHEMBL4095546 | 0.75 | HSP90AB1 (0.38) | SUV39H2HSP90AB1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | claimed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | claimed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | claimed |
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247524-A1 | HSP90 Inhibitor | HSP90AB1, HSP90B1, HSP90AA1 | PTK2 2572/4885SUV39H2 3790/4885HTR4 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.